News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2019
-
Dec 26, 2019
Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Rozlytrek for ROS1-positive Lung Cancer
[PDF 356KB] -
Dec 24, 2019
The Launch of Chugai’s New Corporate Advertisement, “It’s not cancer. It’s one person.”
[PDF 434KB] -
Dec 17, 2019
Notice of Change in Representative Directors
[PDF 110KB] -
Dec 09, 2019
Chugai’s Nemolizumab Receives FDA Breakthrough Therapy Designation for the Treatment of Pruritus Associated with Prurigo Nodularis
[PDF 286KB] -
Dec 06, 2019
“Let’s Learn about Cancer Genomic Medicine,” Chugai’s Website for Patients and the General Public, Won the Asakawa Award in the 7th Web GRAND PRIX
[PDF 248KB] -
Dec 04, 2019
R&I Raises Chugai's Issuer Rating from “AA –” to “AA”
[PDF 327KB] -
Dec 02, 2019
Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25µg/g and Oxarol® Lotion 25µg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
[PDF 116KB] -
Nov 29, 2019
Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online
[PDF 217KB] -
Nov 27, 2019
Chugai and JW Pharmaceutical Agree to Make C&C Research Laboratories, a Joint Venture in Korea, a Wholly Owned Subsidiary of JW Pharmaceutical
[PDF 142KB] -
Nov 27, 2019
Chugai Launches Tecentriq Intravenous Infusion 840 mg as an Optimal Formulation for the Treatment of PD-L1-Positive Inoperable or Metastatic Triple Negative Breast Cancer
[PDF 316KB] -
Nov 20, 2019
Chugai Receives Orphan Drug Designation for Polatuzumab vedotin in Diffuse Large B-Cell Lymphoma from the MHLW
[PDF 206KB] -
Nov 15, 2019
Chugai Wins Prize in 7th WICI Japan Award for Excellence in Integrated Reporting
[PDF 312KB] -
Nov 08, 2019
Chugai Files a New Drug Application for Satralizumab for NMOSD in Japan, Following the United States and Europe
[PDF 245KB] -
Nov 01, 2019
Chugai’s Hemlibra Launched for Hemophiia A with Inhibitors in Taiwan
[PDF 200KB] -
Oct 30, 2019
Chugai’s Hemlibra Approved for Hemophilia A without inhibitors in Taiwan
[PDF 214KB] -
Oct 30, 2019
EMA and FDA Accept Marketing Applications for Chugai's Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 330KB] -
Oct 24, 2019
Chugai Announces 2019 3rd Quarter Results
[PDF 389KB] -
Oct 24, 2019
Notice of Revisions to Financial Forecasts
[PDF 38KB] -
Oct 24, 2019
Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2019
[PDF 22KB] -
Oct 24, 2019
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 135KB] -
Oct 21, 2019
Tecentriq in Combination with Avastin Increases Overall Survival and Progression-free Survival as an Initial Treatment in People with Unresectable Hepatocellular Carcinoma
[PDF 201KB] -
Oct 18, 2019
Data on the use of Chugai’s Hemlibra in Hemophilia A Children with or without Inhibitors were Published in Journals
[PDF 418KB] -
Oct 17, 2019
Relief Efforts Support for Season's Nineteenth Typhoon
[PDF 186KB] -
Oct 16, 2019
Change in Designated Applicant under SAKIGAKE Designation System Concerning “Telomelysin (OBP-301),” Oncolytic Viral Immunotherapy
[PDF 71KB] -
Oct 16, 2019
F. Hoffmann-La Roche Announces Third Quarter Sales 2019
[PDF 107KB] -
Oct 03, 2019
Favorable Ruling in Second Patent Infringement Lawsuit Relating to Chugai’s Hemlibra
[PDF 128KB] -
Sep 30, 2019
A Treatment Support Tool Using a Private Medical Care SNS Becomes Available in Rheumatoid Arthritis, Lupus Nephritis, and Chronic Kidney Disease
[PDF 284KB] -
Sep 25, 2019
Chugai Obtains Approval for the Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Lynparza
[PDF 386KB] -
Sep 25, 2019
Chugai Announces Non-Smoking Declaration
[PDF 295KB] -
Sep 25, 2019
Contribution of Para-transit Vehicles to Welfare Services
[PDF 420KB] -
Sep 20, 2019
Chugai Obtains Approval for Additional Indication and Formulation for Tecentriq in PD-L1-Positive Triple Negative Breast Cancer
[PDF 307KB] -
Sep 18, 2019
Chugai Selected for the Fifth Time and 2nd Consecutive Year for Dow Jones Sustainability Asia Pacific Index
[PDF 190KB] -
Sep 13, 2019
Chugai Receives Orphan Drug Designation for Satralizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder from the Ministry of Health, Labour and Welfare
[PDF 242KB] -
Sep 12, 2019
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
[PDF 214KB] -
Sep 09, 2019
Chugai’s Disease Awareness Website “Let’s Learn about Rheumatoid Arthritis” Adopts FACIL’iti to Enhanse Accessibility
[PDF 414KB] -
Sep 06, 2019
Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Rozlytrek for ROS1-Positive NSCLC
[PDF 298KB] -
Sep 04, 2019
Chugai Launches Rozlytrek, an Anticancer Agent for the Treatment of NTRK Fusion-Positive Solid Tumors
[PDF 309KB] -
Aug 30, 2019
Chugai Files for Additional Indication for Anti-HER2 Antibody Drug Conjugate Kadcyla for Adjuvant Therapy of HER2-Positive Early Breast Cancer
[PDF 200KB] -
Aug 22, 2019
Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer
[PDF 289KB] -
Jul 30, 2019
Chugai Continues to be Listed for All ESG Indices Selected by GPIF
[PDF 201KB] -
Jul 25, 2019
Organizational and Personnel Changes
[PDF 463KB] -
Jul 25, 2019
Chugai Announces 2019 Half Year Results
[PDF 297KB] -
Jul 25, 2019
F. Hoffmann-La Roche Announces Half Year Results 2019
[PDF 107KB] -
Jul 09, 2019
Further Clinical Data including Long-Term Follow-up for Chugai’s Hemlibra Presented at ISTH
[PDF 334KB] -
Jun 27, 2019
Chugai Obtains Approval of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Rozlytrek
[PDF 299KB] -
Jun 18, 2019
Anti-Cancer Agent Rozlytrek, Approved for the Treatment of NTRK Fusion Gene Positive Advanced/Recurrent Solid Tumors
[PDF 297KB] -
Jun 14, 2019
Chugai and Mitsubishi Logistics Enter into Service Agreement for Logistics Operations
[PDF 109KB] -
Jun 03, 2019
Chugai Files for Additional Indication of ALK Inhibitor ALECENSA for Recurrent or Refractory ALK Fusion Gene-Positive Anaplastic Large Cell Lymphoma (ALCL)
[PDF 205KB] -
Jun 03, 2019
Chugai Launches Genomic Mutation Analysis Program, FoundationOne CDx Cancer Genomic Profile
[PDF 207KB] -
Jun 03, 2019
Final Progression-Free Survival Data and the Second Interim Analysis of Overall Survival from the J-ALEX Study for Alecensa Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
[PDF 205KB] -
May 31, 2019
Chugai Conducts Educational Campaign to Promote Cervical Cancer Screening Across Japan with Local Governments and Other Partners
[PDF 384KB] -
May 29, 2019
Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit Concerning Rituxan® Intravenous Infusion
[PDF 21KB] -
May 22, 2019
Chugai’s Actemra Intravenous Infusion Receives Additional Approval for Adult Still’s Disease
[PDF 290KB] -
May 21, 2019
Establishment of Chugai Life Science Park Yokohama and Relocation of Research Laboratories
- Aiming at Creating Innovative New Drugs with Globally Highest Quality - [PDF 186KB] -
Apr 26, 2019
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 112KB] -
Apr 24, 2019
Chugai Announces 2019 1st Quarter Results
[PDF 221KB] -
Apr 24, 2019
Construction of a New Manufacturing Building for Active Pharmaceutical Ingredients to Further Accelerate Development of Small and Middle Molecule Drugs
[PDF 207KB] -
Apr 24, 2019
Implementation and Results of Early Retirement Incentive Program
[PDF 194KB] -
Apr 23, 2019
Chugai Redesigns the Website for Healthcare Professionals
[PDF 387KB] -
Apr 18, 2019
Nemolizumab Shows Positive Results in Maruho’s Phase 3 Study in Atopic Dermatitis
[PDF 188KB] -
Apr 17, 2019
F. Hoffmann-La Roche Announces First Quarter Sales 2019
[PDF 107KB] -
Apr 08, 2019
Conclusion of Exclusive Licensing and Capital Tie-up Agreements Concerning “Telomelysin (OBP-301),” Oncolytic Viral Immunotherapy
[PDF 82KB] -
Apr 01, 2019
Business Transfer of ULCERLMIN® for the Treatment of Gastritis/Peptic Ulcer from Chugai Pharmaceutical to Fuji Chemical Industries
[PDF 102KB] -
Mar 29, 2019
Chugai Files an Application for Expanded Use of Genomic Mutation Analysis Program “FoundationOne CDx Cancer Genomic Profile” as a Companion Diagnostic of Lynparza
[PDF 289KB] -
Mar 29, 2019
Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Continuously Selected as Grant Recipient by GHIT Fund
[PDF 287KB] -
Mar 28, 2019
Personnel Changes
[PDF 190KB] -
Mar 28, 2019
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 131KB] -
Mar 28, 2019
Position and Policy Regarding Reduction of the Investment Unit
[PDF 67KB] -
Mar 27, 2019
Chugai Receives Orphan Drug Designation for Risdiplam in Spinal Muscular Atrophy
[PDF 97KB] -
Mar 26, 2019
Chugai’s Actemra Intravenous Infusion Receives Approval for Additional Indication and Dosing for Cytokine Release Syndrome
[PDF 99KB] -
Mar 26, 2019
Anti-CD20 Monoclonal Antibody “RITUXAN®,” Approved for Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
[PDF 77KB] -
Mar 19, 2019
Miraca and Chugai Enter into Business Partnership Agreement for “FoundationOne® CDx Cancer Genome Profile”
[PDF 141KB] -
Mar 15, 2019
Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer
[PDF 200KB] -
Mar 14, 2019
Chugai’s Hemlibra Receives Approval for Severe Hemophilia A without Factor VIII Inhibitors from the European Commission
[PDF 377KB] -
Mar 11, 2019
Galderma Presented Results from Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis at the 2019 AAD Annual Meeting Late-breaking Session
[PDF 281KB] -
Feb 13, 2019
Chugai’s Actemra, the World’s First Anti-IL-6 Receptor Antibody Created in Japan, Wins Chairman’s Award of Japan Techno-Economics Society
[PDF 93KB] -
Feb 12, 2019
Chugai Wins Second Prize in 21st NIKKEI Annual Report Awards
[PDF 142KB] -
Feb 06, 2019
Together with Roche, Chugai Joins the World Federation of Hemophilia Humanitarian Aid Program
[PDF 178KB] -
Feb 05, 2019
The 1st Japan Open Innovation Prize: Four Parties including Osaka University Win the Minister of Education, Culture, Sports, Science and Technology Award for “University-Industry Co-creation from the Basic Research Stage -Collaboration between Organizations-”
[PDF 230KB] -
Feb 04, 2019
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A without Inhibitors
[PDF 187KB] -
Jan 31, 2019
Chugai Announces 2018 Full Year Results and Forecasts for 2019
[PDF 265KB] -
Jan 31, 2019
Chugai Announces New Mission Statement and New Mid-Term Business Plan “IBI 21,” Striving to Develop Hand in Hand with Society through Creation of Innovative Drugs and Services
[PDF 176KB] -
Jan 31, 2019
Notice of Distribution of Retained Earnings
[PDF 139KB] -
Jan 31, 2019
Organizational and Personnel Changes
[PDF 269KB] -
Jan 31, 2019
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2018
[PDF 70KB] -
Jan 30, 2019
Chugai Transfers Rights to Maruho for Oxarol® Ointment 25µg/g and Oxarol® Lotion 25µg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
[PDF 113KB] -
Jan 18, 2019
Chugai Files an Application for Expanded Use of Genomic Mutation Analysis Program “FoundationOne® CDx Cancer Genomic Profile”
-- Aiming to develop a companion diagnostic for entrectinib -- [PDF 67KB] -
Jan 10, 2019
MI Chat, a ChatBot for Healthcare Professionals, Starts Today to Respond to Inquiries about Product Information
[PDF 115KB] -
Jan 08, 2019
Completion of Transfer of Marketing and Manufacturing Rights of 13 Long-Term Listed Products from Chugai to Taiyo Pharma
[PDF 102KB]